查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654177

醫療保健受託研究機構市場規模、佔有率、趨勢分析報告：按類型、服務、治療領域、分子、地區、細分預測，2025-2030 年

Healthcare Contract Research Organization Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical, And Clinical), By Service, By Therapeutic Area, By Molecule, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

醫療保健研究外包市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球醫療保健受託研究機構市場規模預計到2030年將達到806.1億美元，預計2025年至2030年期間的複合年成長率為7.0%。

預計預測期內藥物開發成本的增加將推動市場需求。此外，臨床試驗成本的上升和患者招募的挑戰促使生物製藥公司將目光投向中歐和東歐、亞太地區、拉丁美洲和中東等地區，以降低成本並加快患者招募。

此外，產業參與者面臨越來越大的滿足嚴格時間表的壓力，這也推動了將研究活動外包給 CRO（受託研究機構）的需求。一些政府機構還將臨床試驗活動外包，以便他們能夠利用必要的基礎設施和專業知識進行臨床試驗，並最大限度地降低成本和時間。

CRO市場暫時受到了疫情的影響，包括臨床試驗地點的關閉。然而，由於治療需求量很大，臨床試驗地點已經重新開放，並採取了一定的措施和預防措施，以避免病毒傳播。此外，全球對尋找冠狀病毒疫苗的關注對針對 COVID-19 的疫苗和藥物開發產生了重大影響。預計這將對市場產生積極影響。

過去五年來，併購交易數量大幅增加。從 2016 年到 2023 年，我們將看到幾起大型合併。此外，大型交易的趨勢似乎在​​ 2021 年及以後逐漸升溫，M&B Sciences Inc. 於 2022 年 3 月收購了 Clara Health，擴大了 M&B Sciences 基於數位技術的臨床試驗的管道。此外，2021年12月，賽默飛世爾宣布收購製藥服務巨頭PPD，2021年2月，ICON plc宣布收購PRA Health Sciences。生物製藥和製藥服務領域使用的分析技術和軟體解決方案正進入整合時代。因此，上述因素支持了市場的成長。

醫療保健受託研究機構市場報告重點

  • 根據類型，臨床部分將在 2024 年主導全球醫療保健 CRO 市場，佔 76.2% 的最大佔有率。這是因為臨床領域包含四個涉及人體受試者研究的複雜階段。對新療法的高需求進一步促進了該領域的成長。
  • 在服務中，臨床監測部門在 2024 年佔據最大的市場佔有率，為 19.91%。
  • 由於多家全球性公司將收益投資於研究活動，北美在 2024 年佔據了 45.50% 的顯著市場佔有率。
  • 預計預測期內亞太地區的醫療保健 CRO 市場將以最快的複合年成長率成長。
  • 由於疾病發生率高，預計中國、日本和印度的藥品受託研究機構市場將顯著成長。由於疾病盛行率高，預計中國、日本和印度的藥品受託研究機構市場將出現巨大的成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

受託研究機構3 章。

  • 市場展望
    • 母市場展望
    • 補貼市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 技術進步
    • 人工智慧與數位科技的融合
  • 贊助商對研發投資的觀點
  • 2024 年臨床試驗數量分析
    • 各地區臨床試驗總數（2024 年）
    • 各階段臨床試驗總數（2024 年）
    • 依研究設計分類的臨床試驗總數（2024 年）
    • 按主要治療領域分類的臨床試驗總數（2024 年）
  • 市場分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析
    • COVID-19影響分析

第 4 章：醫療受託研究機構(CRO) 市場：類型估計與趨勢分析

  • 細分儀表板
  • 全球醫療受託研究機構(CRO) 市場趨勢分析
  • 2018 年至 2030 年全球醫療受託研究機構(CRO) 市場規模與趨勢分析（按類型）
  • 藥物研發
    • 藥物研發和醫療保健受託研究機構市場
    • 目標檢驗
    • 辨識線索
    • 先導藥物最適化
  • 臨床前
    • 臨床前醫療受託研究機構市場
  • 臨床
    • 臨床醫療受託研究機構市場
    • 第一階段試驗服務
    • 第二階段檢測服務
    • III 期臨床試驗服務
    • 第四階段檢測服務

5. 醫療保健受託研究機構(CRO) 市場：服務評估與趨勢分析

  • 細分儀表板
  • 全球醫療受託研究機構(CRO) 市場趨勢分析
  • 2018 年至 2030 年全球醫療受託研究機構(CRO) 市場規模與趨勢分析（按服務分類）
  • 計劃管理/臨床供應管理
    • 計劃管理/臨床供應管理醫療受託研究機構市場
  • 資料管理
    • 資料管理醫療保健受託研究機構市場
  • 監管/醫療
    • 監管/醫療業務醫療保健受託研究機構市場
  • 醫學寫作
    • 醫學寫作醫療保健受託研究機構市場
  • 臨床監測
    • 臨床監測醫療保健受託研究機構市場
  • 品管/保證
    • 品管/保證醫療受託研究機構市場
  • 生物統計學
    • 生物統計醫療受託研究機構市場
  • 支付調查人員費用
    • 研究人員支付醫療受託研究機構市場
  • 實驗室
    • 實驗室醫療保健受託研究機構市場
    • 無菌測試
    • 容器/封蓋測試
    • 萃取物和浸出物測試
    • 環境監測
    • 消毒劑有效性研究
    • 其他
  • 病人和機構招募
    • 病人和設施招募醫療保健受託研究機構市場
  • 科技
    • 技術醫療保健受託研究機構市場
  • 其他
    • 其他醫療受託研究機構市場

6. 醫療受託研究機構(CRO) 市場：治療領域估計與趨勢分析

  • 細分儀表板
  • 全球醫療受託研究機構(CRO) 市場趨勢分析
  • 2018 年至 2030 年全球醫療受託研究機構(CRO) 市場規模及治療領域趨勢分析
  • 腫瘤學
  • 中樞神經系統疾病
  • 感染疾病
  • 免疫系統疾病
  • 心血管疾病
  • 呼吸系統疾病
  • 糖尿病
  • 眼科
  • 疼痛管理
  • 其他

7. 醫療保健受託研究機構(CRO) 市場：分子估計和趨勢分析

  • 細分儀表板
  • 全球醫療受託研究機構(CRO) 市場趨勢分析
  • 2018 年至 2030 年全球醫療保健受託研究機構(CRO) 市場規模和趨勢分析（按分子分類）
  • 藥品
    • 醫藥和醫療保健受託研究機構市場
    • 小分子
    • 生物製藥
  • 醫療設備
    • 醫療設備醫療保健受託研究機構市場

8. 醫療受託研究機構(CRO) 市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030 年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
    • 瑞士
    • 比利時
    • 荷蘭
    • 奧地利
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 台灣
    • 印尼
    • 馬來西亞
    • 新加坡
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 埃及
    • 以色列

第9章 競爭格局

  • 市場參與企業分類
    • 市場領導者
    • 新興企業
  • 2024 年競爭市場佔有率/估值分析
  • 公司簡介
    • ICON Plc
    • Charles River Laboratories
    • Syneos Health
    • IQVIA Inc.
    • GVK Biosciences Private Limited（Aragen）
    • LabCorp
    • Parexel International Corporation
    • WuXi AppTec
    • Thermo Fisher Scientific Inc.
    • CTI Clinical Trial &Consulting
    • PSI
    • Medpace
    • Ergomed
    • Worldwide Clinical Trials
    • Medidata Solutions, Inc.
    • Pharmaron GMBH
    • SGS SA
    • KCR SA
    • Advanced Clinical Research Services, LLC.
    • Pharm-Olam, LLC（Allucent）
Product Code: 978-1-68038-688-2

Healthcare Contract Research Organization Market Growth & Trends:

The global healthcare contract research organization market size is estimated to reach USD 80.61 billion by 2030, registering to grow at a CAGR of 7.0% from 2025 to 2030 according to a new report by Grand View Research, Inc. The increasing cost of drug development is expected to drive market demand over the forecast period. Also, rising clinical trials cost and challenges pertaining to patient recruitment have led biopharmaceutical companies to turn to regions like Central and Eastern Europe, Asia Pacific, Latin America, and the Middle East for cost savings and quick patient recruitment.

In addition, growing pressure on industry players to follow stringent timelines has increased the demand for outsourcing research activities to contract research organizations (CROs). Some government organizations are also outsourcing their clinical trial activities so that they can carry out clinical trials with the required infrastructure and expertise and minimize their cost and timelines.

The CRO market was temporarily affected by the ongoing pandemic, as it led to the closure of clinical trial sites. However, owing to the significant demand for treatments, the clinical trial sites were reopened with certain measures and precautions to avoid the spread of the virus. Moreover, the worldwide focus on finding a vaccine against coronavirus has had a significant impact on the development of vaccines & drugs for COVID-19. This is expected to have a positive impact on the market.

Over the past 5 years, the number of mergers and acquisitions significantly increased. Several large mergers have been witnessed since 2016 till 2023. Moreover, the trend of large transactions seems to be picking up since 2021, as in March 2022, M&B Sciences Inc, acquired Clara Health, which expanded M&B Sciences' access to digital technology-based clinical trials. Moreover, in December 2021, Thermo Fisher announced the acquisition of pharmaceutical services giant PPD, and in February 2021, ICON plc announced the acquisition of PRA Health Sciences. An era of consolidation has been witnessed around analytical technologies and software solutions used in the biopharmaceutical and pharmaceutical companies' services space. Hence, the aforementioned factors supported the market's growth.

Healthcare Contract Research Organization Market Report Highlights:

  • Based on type, the clinical segment has dominated the global healthcare CRO market in 2024, with the largest share of 76.2% owing to the fact that it comprises four elaborate phases, including human subjects. The significant demand for new treatments has further contributed to the growth of the segment.
  • Among services, the clinical monitoring segment was the largest in terms of market share at 19.91% in 2024.
  • North America held a significant market share of 45.50% in 2024 due to the presence of several global players who invest a major part of their revenue in research activities.
  • The healthcare Contract Research Organizations market in Asia Pacific is expected to grow at the fastest CAGR over the forecast period.
  • China, Japan, and India are projected to witness tremendous growth in the contract research organization market owing to high disease prevalence. China, Japan, and India are projected to witness tremendous growth in the contract research organization market owing to high disease prevalence.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Healthcare Contract Research Organizations (CRO) Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Rate of Clinical Research To Boost Demand For Outsourcing Services
      • 3.2.1.2. Increasing Adoption Of Advanced Technologies
      • 3.2.1.3. Increasing Mergers and Collaborations
      • 3.2.1.4. Increasing Demand For Outsourcing Services Across The Developing Economies
      • 3.2.1.5. Patent Cliff
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Quality issues of CRO services
      • 3.2.2.2. Intellectual property rights issues
  • 3.3. Technological Advancements
    • 3.3.1. Integration of AI and digital technologies
  • 3.4. R&D Investment Perspective, by Sponsors
  • 3.5. Clinical Trials Volume Analysis, 2024
    • 3.5.1. Total Number of Clinical Trials, by Region (2024)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2024)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2024)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL by SWOT Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Healthcare Contract Research Organizations (CRO) Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
  • 4.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Type, 2018 - 2030 (USD Million)
  • 4.4. Drug Discovery
    • 4.4.1. Drug Discovery Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 4.4.2. Target Validation
      • 4.4.2.1. Target Validation Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 4.4.3. Lead Identification
      • 4.4.3.1. Lead Identification Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 4.4.4. Lead Optimization
      • 4.4.4.1. Lead Optimization Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.5. Pre-clinical
    • 4.5.1. Pre-clinical Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6. Clinical
    • 4.6.1. Clinical Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 4.6.2. Phase I Trial Services
      • 4.6.2.1. Phase I Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 4.6.3. Phase II Trial Services
      • 4.6.3.1. Phase II Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 4.6.4. Phase III Trial Services
      • 4.6.4.1. Phase III Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 4.6.5. Phase IV Trial Services
      • 4.6.5.1. Phase IV Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 5. Healthcare Contract Research Organizations (CRO) Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
  • 5.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Service, 2018 - 2030 (USD Million)
  • 5.4. Project Management/Clinical Supply Management
    • 5.4.1. Project Management/Clinical Supply Management Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.5. Data Management
    • 5.5.1. Data Management Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.6. Regulatory/Medical Affairs
    • 5.6.1. Regulatory/Medical Affairs Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.7. Medical Writing
    • 5.7.1. Medical Writing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.8. Clinical Monitoring
    • 5.8.1. Clinical Monitoring Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.9. Quality Management/Assurance
    • 5.9.1. Quality Management/Assurance Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.10. Bio-statistics
    • 5.10.1. Bio-statistics Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.11. Investigator Payments
    • 5.11.1. Investigator Payments Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12. Laboratory
    • 5.12.1. Laboratory Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 5.12.2. Sterility Testing
      • 5.12.2.1. Sterility Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 5.12.3. Container/Closure Testing
      • 5.12.3.1. Container/Closure Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 5.12.4. Extractables and Leachable Testing
      • 5.12.4.1. Extractables and Leachable Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 5.12.5. Environmental Monitoring
      • 5.12.5.1. Environmental Monitoring Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 5.12.6. Disinfectant Efficacy Studies
      • 5.12.6.1. Disinfectant Efficacy Studies Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 5.12.7. Others
      • 5.12.7.1. Others Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.13. Patient and Site Recruitment
    • 5.13.1. Patient and Site Recruitment Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.14. Technology
    • 5.14.1. Technology Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.15. Others
    • 5.15.1. Others Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 6. Healthcare Contract Research Organizations (CRO) Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
  • 6.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. CNS Disorders
    • 6.5.1. CNS Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Infectious Diseases
    • 6.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Immunological Disorders
    • 6.7.1. Immunological Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Cardiovascular Diseases
    • 6.8.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Respiratory Diseases
    • 6.9.1. Respiratory Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. Diabetes
    • 6.10.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.11. Ophthalmology
    • 6.11.1. Ophthalmology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.12. Pain Management
    • 6.12.1. Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.13. Others
    • 6.13.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Healthcare Contract Research Organizations (CRO) Market: Molecule Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
  • 7.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Molecule, 2018 - 2030 (USD Million)
  • 7.4. Pharmaceuticals
    • 7.4.1. Pharmaceuticals Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 7.4.2. Small Molecules
      • 7.4.2.1. Small Molecules Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
    • 7.4.3. Biologics
      • 7.4.3.1. Biologics Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 7.5. Medical Device
    • 7.5.1. Medical Device Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 8. Healthcare Contract Research Organizations (CRO) Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Global Regional Market Snapshot
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.10. Switzerland
      • 8.5.10.1. Key Country Dynamics
      • 8.5.10.2. Competitive Scenario
      • 8.5.10.3. Regulatory Framework
      • 8.5.10.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.11. Belgium
      • 8.5.11.1. Key Country Dynamics
      • 8.5.11.2. Competitive Scenario
      • 8.5.11.3. Regulatory Framework
      • 8.5.11.4. Belgium Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.12. Netherlands
      • 8.5.12.1. Key Country Dynamics
      • 8.5.12.2. Competitive Scenario
      • 8.5.12.3. Regulatory Framework
      • 8.5.12.4. Netherlands Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.13. Austria
      • 8.5.13.1. Key Country Dynamics
      • 8.5.13.2. Competitive Scenario
      • 8.5.13.3. Regulatory Framework
      • 8.5.13.4. Austria Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Japan
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.8. Taiwan
      • 8.6.8.1. Key Country Dynamics
      • 8.6.8.2. Competitive Scenario
      • 8.6.8.3. Regulatory Framework
      • 8.6.8.4. Taiwan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.9. Indonesia
      • 8.6.9.1. Key Country Dynamics
      • 8.6.9.2. Competitive Scenario
      • 8.6.9.3. Regulatory Framework
      • 8.6.9.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.10. Malaysia
      • 8.6.10.1. Key Country Dynamics
      • 8.6.10.2. Competitive Scenario
      • 8.6.10.3. Regulatory Framework
      • 8.6.10.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.11. Singapore
      • 8.6.11.1. Key Country Dynamics
      • 8.6.11.2. Competitive Scenario
      • 8.6.11.3. Regulatory Framework
      • 8.6.11.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.4. Colombia
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Competitive Scenario
      • 8.7.4.3. Regulatory Framework
      • 8.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.5. Chile
      • 8.7.5.1. Key Country Dynamics
      • 8.7.5.2. Competitive Scenario
      • 8.7.5.3. Regulatory Framework
      • 8.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.6. Egypt
      • 8.8.6.1. Key Country Dynamics
      • 8.8.6.2. Competitive Scenario
      • 8.8.6.3. Regulatory Framework
      • 8.8.6.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.7. Israel
      • 8.8.7.1. Key Country Dynamics
      • 8.8.7.2. Competitive Scenario
      • 8.8.7.3. Regulatory Framework
      • 8.8.7.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Competitive Market Share/Assessment Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. ICON Plc
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Charles River Laboratories
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Syneos Health
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. IQVIA Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. GVK Biosciences Private Limited (Aragen)
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. LabCorp
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Parexel International Corporation
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. WuXi AppTec
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Thermo Fisher Scientific Inc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. CTI Clinical Trial & Consulting
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. PSI
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Medpace
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. Ergomed
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Worldwide Clinical Trials
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Medidata Solutions, Inc.
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Financial Performance
      • 9.3.15.3. Service Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. Pharmaron GMBH
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Financial Performance
      • 9.3.16.3. Service Benchmarking
      • 9.3.16.4. Strategic Initiatives
    • 9.3.17. SGS SA
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Financial Performance
      • 9.3.17.3. Service Benchmarking
      • 9.3.17.4. Strategic Initiatives
    • 9.3.18. KCR S.A.
      • 9.3.18.1. Company Overview
      • 9.3.18.2. Financial Performance
      • 9.3.18.3. Service Benchmarking
      • 9.3.18.4. Strategic Initiatives
    • 9.3.19. Advanced Clinical Research Services, LLC.
      • 9.3.19.1. Company Overview
      • 9.3.19.2. Financial Performance
      • 9.3.19.3. Service Benchmarking
      • 9.3.19.4. Strategic Initiatives
    • 9.3.20. Pharm-Olam, LLC (Allucent)
      • 9.3.20.1. Company Overview
      • 9.3.20.2. Financial Performance
      • 9.3.20.3. Service Benchmarking
      • 9.3.20.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 5 Global Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 6 Global Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 7 Global Nucleic Acid Therapeutics CDMO, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 10 North America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 11 North America Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 12 North America Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 13 U.S. Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 15 U.S. Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 16 U.S. Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 17 Canada Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 18 Canada Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 19 Canada Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 20 Canada Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 21 Mexico Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 22 Mexico Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 23 Mexico Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 24 Mexico Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 25 Europe Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 27 Europe Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 28 Europe Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 29 Europe Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 30 Germany Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 32 Germany Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 33 Germany Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 34 UK Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 35 UK Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 36 UK Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 37 UK Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 38 France Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 39 France Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 40 France Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 41 France Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 42 Italy Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 43 Italy Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 44 Italy Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 45 Italy Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 46 Spain Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 47 Spain Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 48 Spain Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 49 Spain Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 50 Denmark Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 51 Denmark Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 52 Denmark Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 53 Denmark Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 54 Sweden Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 55 Sweden Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 56 Sweden Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 57 Sweden Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 58 Norway Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 59 Norway Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 60 Norway Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 61 Norway Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 62 Switzerland Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 63 Switzerland Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 64 Switzerland Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 65 Switzerland Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 66 Belgium Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 67 Belgium Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 68 Belgium Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 69 Belgium Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 70 Netherlands Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 71 Netherlands Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 72 Netherlands Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 73 Netherlands Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 74 Austria Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 75 Austria Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 76 Austria Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 77 Austria Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 78 Asia Pacific Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 79 Asia Pacific Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 80 Asia Pacific Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 81 Asia Pacific Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 82 Asia Pacific Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 83 China Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 84 China Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 85 China Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 86 China Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 87 Japan Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 88 Japan Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 89 Japan Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 90 Japan Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 91 India Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 92 India Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 93 India Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 94 India Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 95 South Korea Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 96 South Korea Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 97 South Korea Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 98 South Korea Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 99 Australia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 100 Australia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 101 Australia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 102 Australia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 103 Thailand Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 104 Thailand Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 105 Thailand Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 106 Thailand Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 107 Taiwan Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 108 Taiwan Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 109 Taiwan Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 110 Taiwan Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 111 Indonesia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 112 Indonesia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 113 Indonesia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 114 Indonesia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 115 Malaysia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 116 Malaysia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 117 Malaysia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 118 Malaysia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 119 Singapore Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 120 Singapore Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 121 Singapore Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 122 Singapore Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 123 Latin America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 124 Latin America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 125 Latin America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 126 Latin America Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 127 Latin America Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 128 Brazil Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 129 Brazil Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 130 Brazil Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 131 Brazil Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 132 Argentina Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 133 Argentina Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 134 Argentina Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 135 Argentina Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 136 Colombia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 137 Colombia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 138 Colombia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 139 Colombia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 140 Chile Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 141 Chile Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 142 Chile Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 143 Chile Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 144 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 145 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 146 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 147 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 148 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 149 South Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 150 South Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 151 South Africa Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 152 South Africa Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 153 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 154 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 155 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 156 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 157 UAE Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 158 UAE Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 159 UAE Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 160 UAE Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 161 Kuwait Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 162 Kuwait Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 163 Kuwait Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 164 Kuwait Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 165 Egypt Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 166 Egypt Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 167 Egypt Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 168 Egypt Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
  • Table 169 Israel Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 170 Israel Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 171 Israel Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 172 Israel Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Healthcare Contract Research Organizations (CRO), Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Healthcare Contract Research Organizations (CRO), for Drug Discovery, 2018 - 2030 (USD Million)
  • Fig. 13 Global Healthcare Contract Research Organizations (CRO), for Target Validation, 2018 - 2030 (USD Million)
  • Fig. 14 Global Healthcare Contract Research Organizations (CRO), for Lead Identification, 2018 - 2030 (USD Million)
  • Fig. 15 Global Healthcare Contract Research Organizations (CRO), for Lead Optimization, 2018 - 2030 (USD Million)
  • Fig. 16 Global Healthcare Contract Research Organizations (CRO), for Pre-Clinical, 2018 - 2030 (USD Million)
  • Fig. 17 Global Healthcare Contract Research Organizations (CRO), for Clinical, 2018 - 2030 (USD Million)
  • Fig. 18 Global Healthcare Contract Research Organizations (CRO), for Phase I Trials, 2018 - 2030 (USD Million)
  • Fig. 19 Global Healthcare Contract Research Organizations (CRO), for Phase II Trials, 2018 - 2030 (USD Million)
  • Fig. 20 Global Healthcare Contract Research Organizations (CRO), for Phase III Trials, 2018 - 2030 (USD Million)
  • Fig. 21 Global Healthcare Contract Research Organizations (CRO), for Phase IV Trials, 2018 - 2030 (USD Million)
  • Fig. 22 Global Healthcare Contract Research Organizations (CRO), for Project Management/Clinical Supply Management, 2018 - 2030 (USD Million)
  • Fig. 23 Global Healthcare Contract Research Organizations (CRO), for Data Management, 2018 - 2030 (USD Million)
  • Fig. 24 Global Healthcare Contract Research Organizations (CRO), for Regulatory/Medical Affairs, 2018 - 2030 (USD Million)
  • Fig. 25 Global Healthcare Contract Research Organizations (CRO), for Medical Writing, 2018 - 2030 (USD Million)
  • Fig. 26 Global Healthcare Contract Research Organizations (CRO), for Clinical Monitoring, 2018 - 2030 (USD Million)
  • Fig. 27 Global Healthcare Contract Research Organizations (CRO), for Quality Management/ Assurance, 2018 - 2030 (USD Million)
  • Fig. 28 Global Healthcare Contract Research Organizations (CRO), for Bio-statistics, 2018 - 2030 (USD Million)
  • Fig. 29 Global Healthcare Contract Research Organizations (CRO), for Investigator Payments , 2018 - 2030 (USD Million)
  • Fig. 30 Global Healthcare Contract Research Organizations (CRO), for Laboratory, 2018 - 2030 (USD Million)
  • Fig. 31 Global Healthcare Contract Research Organizations (CRO), for Sterility Testing, 2018 - 2030 (USD Million)
  • Fig. 32 Global Healthcare Contract Research Organizations (CRO), for Container/Closure Testing, 2018 - 2030 (USD Million)
  • Fig. 33 Global Healthcare Contract Research Organizations (CRO), for Extractables and Leachable Testing, 2018 - 2030 (USD Million)
  • Fig. 34 Global Healthcare Contract Research Organizations (CRO), for Environmental Monitoring (Including Microbiology Testing), 2018 - 2030 (USD Million)
  • Fig. 35 Global Healthcare Contract Research Organizations (CRO), for Disinfectant Efficacy Studies, 2018 - 2030 (USD Million)
  • Fig. 36 Global Healthcare Contract Research Organizations (CRO), for Others, 2018 - 2030 (USD Million)
  • Fig. 37 Global Healthcare Contract Research Organizations (CRO), for Patient and Site Recruitment , 2018 - 2030 (USD Million)
  • Fig. 38 Global Healthcare Contract Research Organizations (CRO), for Technology , 2018 - 2030 (USD Million)
  • Fig. 39 Global Healthcare Contract Research Organizations (CRO), for Others, 2018 - 2030 (USD Million)
  • Fig. 40 Global Healthcare Contract Research Organizations (CRO), for Oncology , 2018 - 2030 (USD Million)
  • Fig. 41 Global Healthcare Contract Research Organizations (CRO), for CNS Disorders , 2018 - 2030 (USD Million)
  • Fig. 42 Global Healthcare Contract Research Organizations (CRO), for Infectious Diseases , 2018 - 2030 (USD Million)
  • Fig. 43 Global Healthcare Contract Research Organizations (CRO), for Immunological Disorders , 2018 - 2030 (USD Million)
  • Fig. 44 Global Healthcare Contract Research Organizations (CRO), for Cardiovascular Diseases, 2018 - 2030 (USD Million)
  • Fig. 45 Global Healthcare Contract Research Organizations (CRO), for Respiratory Diseases , 2018 - 2030 (USD Million)
  • Fig. 46 Global Healthcare Contract Research Organizations (CRO), for Diabetes , 2018 - 2030 (USD Million)
  • Fig. 47 Global Healthcare Contract Research Organizations (CRO), for Ophthalmology , 2018 - 2030 (USD Million)
  • Fig. 48 Global Healthcare Contract Research Organizations (CRO), for Pain Management, 2018 - 2030 (USD Million)
  • Fig. 49 Global Healthcare Contract Research Organizations (CRO), for Others, 2018 - 2030 (USD Million)
  • Fig. 50 Global Healthcare Contract Research Organizations (CRO), for Pharmaceuticals, 2018 - 2030 (USD Million)
  • Fig. 51 Global Healthcare Contract Research Organizations (CRO), for Small Molecules, 2018 - 2030 (USD Million)
  • Fig. 52 Global Healthcare Contract Research Organizations (CRO), for Biologics, 2018 - 2030 (USD Million)
  • Fig. 53 Global Healthcare Contract Research Organizations (CRO), for Medical Device, 2018 - 2030 (USD Million)
  • Fig. 54 Regional Outlook, 2024 & 2030
  • Fig. 55 North America Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 US Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Canada Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Mexico Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Europe Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UK Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Germany Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 France Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Italy Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Spain Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Denmark Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Sweden Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Norway Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Switzerland Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Belgium Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Netherlands Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Austria Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Asia Pacific Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 India Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 China Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Japan Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Australia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Thailand Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Taiwan Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Indonesia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Malaysia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Singapore Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Brazil Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Colombia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Chile Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 MEA Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 UAE Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Egypt Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Israel Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)